CA-ANDERSEN-GLOBAL
5.6.2022 13:07:14 CEST | Business Wire | Pressemeddelelse
Andersen Global fortsætter med at styrke sin internationale tilstedeværelse idet Andersen i Georgien (tidligere Prime Tax LLC) debuterer i Centralasien. Andersen Global byder også velkommen til medlemsfirmaet MG Law, et Tbilisi-baseret advokatfirma og samarbejdende firma siden 2020. Sammen vil de to medlemsfirmaer levere en komplet pakke af integrerede skatte- og juridiske tjenester til klienter i Georgien og i udlandet.
"Georgiens skattelandskab bliver mere komplekst, og vores erfarne team arbejder flittigt på at levere omfattende tjenester af høj kvalitet til vores lokale og internationale kunder," siger Zurab Nikvashvili, ledende partner, Andersen i Georgien. "Ved at indføre Andersen-brandet vil vores firma være i stand til at udvide vores kompetencer og levere innovative løsninger uanset landegrænser."
Andersen i Georgien tilbyder kunderne en bred vifte af skatte-, regnskabs- og forretningsrådgivningstjenester, herunder rapportering og overholdelse af skatteregler, outsourcet regnskab, skattetvistbilæggelse, skatterådgivning, international skat, transfer pricing og M&A-tjenester. Vedvarende anerkendt af The Legal 500 , er MG Law et fuld service advokatfirma, der specialiserer sig i bank og finans, ansættelsesret, voldgifts- og retssager, fast ejendom, skat og told, selskabsret, og kryptovaluta og blockchain. Begge medlemsvirksomheder betjener lokale og internationale kunder, herunder finansielle institutioner, investeringsfonde, statslige institutioner og offentlige virksomheder.
MG Law’s ledende partner Archil Giorgadze tilføjer: "Vi mener, at nøglen til at levere den bedste kundeservice i klassen er at sikre, at vores fagfolk har forskellig brancheerfaring og multijurisdiktionelle baggrunde. Ved at blive medlem af Andersen Global er vi i stand til at styrke vores teams viden og erfaring ved at udnytte ressourcerne i den globale organisation."
"Andersen i Georgien og MG Law er førende ledere inden for skatte- og juridiske sektorer, og deres engagement i deres kunder kendetegner vores tilpassede værdier som en sammenhængende global organisation," siger formand for Andersen Global og CEO for Andersen, Mark Vorsatz. "Deres optagelse som medlemsfirmaer viser vores dedikation for at give vores kunder omfattende, sømløse løsninger globalt."
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer, bestående af skatte- og juraeksperter i hele verden. Andersen Global blev stiftet af den amerikanske medlemsvirksomhed Andersen Tax LLC i 2013 og Andersen Global har nu over 11.000 fagfolk globalt og er repræsenteret på mere end 360 lokaliteter via sine medlemsvirksomheder og samarbejdende virksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220602005193/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
